Arvinas, Inc. (ARVN)
| Market Cap | 667.75M +44.3% |
| Revenue (ttm) | 262.60M -0.3% |
| Net Income | -80.80M |
| EPS | -1.14 |
| Shares Out | 63.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 635,130 |
| Open | 10.39 |
| Previous Close | 10.42 |
| Day's Range | 10.15 - 10.52 |
| 52-Week Range | 5.90 - 14.51 |
| Beta | 1.98 |
| Analysts | Buy |
| Price Target | 15.05 (+44.16%) |
| Earnings Date | May 4, 2026 |
About ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, suc... [Read more]
Financial Performance
In 2025, Arvinas's revenue was $262.60 million, a decrease of -0.30% compared to the previous year's $263.40 million. Losses were -$80.80 million, -59.38% less than in 2024.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for ARVN stock is "Buy." The 12-month stock price target is $15.05, which is an increase of 44.16% from the latest price.
News
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days
– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson's disease and progressive supranuclear palsy –
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson's disease –
Arvinas Transcript: Barclays 28th Annual Global Healthcare Conference
Four clinical programs are in phase I, with vepdegestrant awaiting FDA approval and partnership. LRRK2 and KRAS degraders show strong differentiation and rapid progress, with key data readouts and new trials expected this year. Multiple milestones are targeted through 2026.
Arvinas Transcript: Leerink Global Healthcare Conference 2026
The conference highlighted a robust early-stage pipeline with multiple phase I programs, including promising data for LRRK2 and KRAS G12D degraders. Strategic focus is on asset differentiation and advancing clinical candidates, with key data readouts expected this year.
Arvinas Transcript: TD Cowen 46th Annual Health Care Conference
Four phase I programs are advancing, including LRRK2 and KRAS G12D degraders, with key data readouts expected in 2024 and 2026. Oncology and neurology pipelines show robust preclinical and early clinical results, and strategic partnerships and commercialization efforts are ongoing.
Arvinas Earnings Call Transcript: Q4 2025
2025 saw major pipeline progress, cost reductions, and a strong cash position supporting clinical milestones into 2028. Multiple phase I programs in oncology, neurology, and rare disease are advancing, with key data readouts expected in 2026.
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-1...
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb. 12, ...
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma...
Arvinas Transcript: Piper Sandler 37th Annual Healthcare Conference
Multiple PROTAC pipeline programs are advancing, including LRRK2, BCL6, KRAS G12D, and polyQ AR degraders, with key clinical milestones expected next year. Strong cash reserves support development into 2028, with potential for further funding from out-licensing.
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...
Arvinas Transcript: Jefferies London Healthcare Conference 2025
A strategic reset has prioritized five early-stage assets, with LRRK2 and PSP leading the pipeline and key data readouts expected in 2026. Vepdegestrant is being actively partnered, and the company maintains a strong cash position into 2028. Oncology programs, including BCL6, are also advancing.
Arvinas Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The discussion highlighted progress in protein degrader technology, with five clinical-stage drugs and two more entering trials next year. Key programs include vepdegestrant nearing approval, ARV-102 for neurodegeneration, and new efforts in SBMA and immuno-oncology.
Arvinas Earnings Call Transcript: Q3 2025
Q3 2025 saw strong clinical and preclinical progress across oncology and neurology, with robust early data from ARV-102, ARV-806, and ARV-393. Revenue and expenses declined year-over-year, and a $100M share repurchase was initiated. Cash runway extends into 2028.
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson's disease – – Presented preclinical data from ARV-806 demonstrating robust and dif...
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
NEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer –
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
– Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including p...
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today an...
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease –